Intravenous tissue plasminogen activator in patients with stroke increases the bioavailability of insulin-like growth factor-1

Nadine Wilczak; Jan Willem Elting; Daniel Chesik; Ido P. Kema; Jacques De Keyser

doi:10.1161/01.STR.0000236496.30106.4b

Intravenous tissue plasminogen activator in patients with stroke increases the bioavailability of insulin-like growth factor-1

Nadine Wilczak
, Jan Willem Elting
, Daniel Chesik
, Ido P. Kema
, Jacques De Keyser^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

14 Citations (Scopus)

Abstract

Background and Purpose-Insulin-like growth factor (IGF)-1 has potent neuroprotective properties. We investigated the effects of intravenous administration of tissue plasminogen activator (tPA) on serum levels of IGF-1 and IGF-binding protein (IGFBP)-3 in patients with acute ischemic stroke.

Methods-Serum levels of total IGF-1, free IGF-1, and IGFBP-3 were measured by radioimmunoassay in 10 patients with ischemic stroke treated with intravenous tPA (0.9 mg/kg body weight) and 10 untreated controls.

Results-During tPA treatment, total IGF-1 and IGFBP-3 serum levels did not change, but there was an approximate to 70% increase in free IGF-1 serum levels from 0.98 +/- 0.25 at baseline to 1.69 +/- 0.18 nmol/L at the end of the I-hour infusion (P=0.01). Conclusions-Intravenous therapy with tPA enhances the bioavailability of IGF-1.

Conclusions-Intravenous therapy with tPA enhances the bioavailability of IGF-1.

Original language	English
Pages (from-to)	2368-2371
Number of pages	4
Journal	Stroke
Volume	37
Issue number	9
DOIs	https://doi.org/10.1161/01.STR.0000236496.30106.4b
Publication status	Published - Sept-2006

Keywords

acute stroke
insulin-like growth factor 1
neuroprotection
thrombolysis
tissue plasminogen activator
FOCAL CEREBRAL-ISCHEMIA
TPA-DEFICIENT MICE
NEURONAL DAMAGE
BRAIN-INJURY
WILD-TYPE
RATS
PROTEIN-3
MODELS

Access to Document

10.1161/01.STR.0000236496.30106.4b

Handle.net

Persistent link

Cite this

@article{3a051cb6b2be4fb5ac9af853fa5f5c63,

title = "Intravenous tissue plasminogen activator in patients with stroke increases the bioavailability of insulin-like growth factor-1",

abstract = "Background and Purpose-Insulin-like growth factor (IGF)-1 has potent neuroprotective properties. We investigated the effects of intravenous administration of tissue plasminogen activator (tPA) on serum levels of IGF-1 and IGF-binding protein (IGFBP)-3 in patients with acute ischemic stroke.Methods-Serum levels of total IGF-1, free IGF-1, and IGFBP-3 were measured by radioimmunoassay in 10 patients with ischemic stroke treated with intravenous tPA (0.9 mg/kg body weight) and 10 untreated controls.Results-During tPA treatment, total IGF-1 and IGFBP-3 serum levels did not change, but there was an approximate to 70\% increase in free IGF-1 serum levels from 0.98 +/- 0.25 at baseline to 1.69 +/- 0.18 nmol/L at the end of the I-hour infusion (P=0.01). Conclusions-Intravenous therapy with tPA enhances the bioavailability of IGF-1.Conclusions-Intravenous therapy with tPA enhances the bioavailability of IGF-1.",

keywords = "acute stroke, insulin-like growth factor 1, neuroprotection, thrombolysis, tissue plasminogen activator, FOCAL CEREBRAL-ISCHEMIA, TPA-DEFICIENT MICE, NEURONAL DAMAGE, BRAIN-INJURY, WILD-TYPE, RATS, PROTEIN-3, MODELS",

author = "Nadine Wilczak and Elting, \{Jan Willem\} and Daniel Chesik and Kema, \{Ido P.\} and \{De Keyser\}, Jacques",

note = "Article J",

year = "2006",

month = sep,

doi = "10.1161/01.STR.0000236496.30106.4b",

language = "English",

volume = "37",

pages = "2368--2371",

journal = "Stroke",

issn = "0039-2499",

publisher = "Lippincott Williams and Wilkins",

number = "9",

}

TY - JOUR

T1 - Intravenous tissue plasminogen activator in patients with stroke increases the bioavailability of insulin-like growth factor-1

AU - Wilczak, Nadine

AU - Elting, Jan Willem

AU - Chesik, Daniel

AU - Kema, Ido P.

AU - De Keyser, Jacques

N1 - Article J

PY - 2006/9

Y1 - 2006/9

N2 - Background and Purpose-Insulin-like growth factor (IGF)-1 has potent neuroprotective properties. We investigated the effects of intravenous administration of tissue plasminogen activator (tPA) on serum levels of IGF-1 and IGF-binding protein (IGFBP)-3 in patients with acute ischemic stroke.Methods-Serum levels of total IGF-1, free IGF-1, and IGFBP-3 were measured by radioimmunoassay in 10 patients with ischemic stroke treated with intravenous tPA (0.9 mg/kg body weight) and 10 untreated controls.Results-During tPA treatment, total IGF-1 and IGFBP-3 serum levels did not change, but there was an approximate to 70% increase in free IGF-1 serum levels from 0.98 +/- 0.25 at baseline to 1.69 +/- 0.18 nmol/L at the end of the I-hour infusion (P=0.01). Conclusions-Intravenous therapy with tPA enhances the bioavailability of IGF-1.Conclusions-Intravenous therapy with tPA enhances the bioavailability of IGF-1.

AB - Background and Purpose-Insulin-like growth factor (IGF)-1 has potent neuroprotective properties. We investigated the effects of intravenous administration of tissue plasminogen activator (tPA) on serum levels of IGF-1 and IGF-binding protein (IGFBP)-3 in patients with acute ischemic stroke.Methods-Serum levels of total IGF-1, free IGF-1, and IGFBP-3 were measured by radioimmunoassay in 10 patients with ischemic stroke treated with intravenous tPA (0.9 mg/kg body weight) and 10 untreated controls.Results-During tPA treatment, total IGF-1 and IGFBP-3 serum levels did not change, but there was an approximate to 70% increase in free IGF-1 serum levels from 0.98 +/- 0.25 at baseline to 1.69 +/- 0.18 nmol/L at the end of the I-hour infusion (P=0.01). Conclusions-Intravenous therapy with tPA enhances the bioavailability of IGF-1.Conclusions-Intravenous therapy with tPA enhances the bioavailability of IGF-1.

KW - acute stroke

KW - insulin-like growth factor 1

KW - neuroprotection

KW - thrombolysis

KW - tissue plasminogen activator

KW - FOCAL CEREBRAL-ISCHEMIA

KW - TPA-DEFICIENT MICE

KW - NEURONAL DAMAGE

KW - BRAIN-INJURY

KW - WILD-TYPE

KW - RATS

KW - PROTEIN-3

KW - MODELS

U2 - 10.1161/01.STR.0000236496.30106.4b

DO - 10.1161/01.STR.0000236496.30106.4b

M3 - Article

SN - 0039-2499

VL - 37

SP - 2368

EP - 2371

JO - Stroke

JF - Stroke

IS - 9

ER -

Intravenous tissue plasminogen activator in patients with stroke increases the bioavailability of insulin-like growth factor-1

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this